21-23 October 2018 | Radisson Blu Hotel - Berlin, Germany
Ornah Levine-Dolberg, MD
(MAPS EMEA President) / Vice President & Global Head of Medical Affairs / Research & Development / Glenmark Pharmaceuticals
Dr. Ornah Levine-Dolberg graduated from the Ben Gurion University, Medical School in 1990. Following her residency in Psychiatry completed cum laude, she was the Director of the Day Hospital at the Sheeba Medical Center in Israel for 7 years. Her first industry role was in 2003 as a Country Medical Director for Lundbeck. After 3 years in that role she moved to Copenhagen to take up various roles in Global Medical Affairs, including heading the department of Scientific Communications, responsibility for a competitive ISS program, and being the Global Medical Director for escitalopram, a highly successful treatment for Mood and Anxiety Disorders. One of her final roles in Lundbeck was the launch of escitalopram in China.
Dr Ornah Levine-Dolberg joined Teva Pharmaceuticals in mid-2013 to head the newly formed Medical Affairs, Growth Markets. From a team of 2 this department has grown to more than 100 employees. Dr Levine-Dolberg established all functions in this team including Medical Operations and Excellence, Therapeutic Area Leads and their operating model, Country Medical Directors and their departmental structures and deliverables. On a regional level, she built various infrastructure capabilities such as Medical Information, promotional material review, governance bodies, operating models, KPIs, financial structures, and a strategic project called Signature Medical Moves. In addition, Ornah was part of the leadership team of Growth Markets and a prominent member of the Global Medical Affairs Leadership team.
In September 2016 Ornah joined Glenmark Pharmaceuticals in their London headquarters to establish and launch Global Medical Affairs and to help the company in its transition from a medium sized Indian company to a global presence with expertise in all facets of drug development and commercialization.
Senior Med Affairs Professional/ Formerly GSK, SVP Global Medical Affairs
Danie is a senior pharmaceutical executive with 25 years’ experience mainly in medical affairs. He has a passion for modernising medical affairs and track record in leadership, people development, capability building and coaching. Danie is a qualified MD with a Masters in Clinical Pharmacology who combines medical and life science qualifications with an MBA. Danie has extensive experience building international teams, driving change and working in regulated markets for GlaxoSmithKline (GSK) across Europe, the Americas, Middle East, Africa, Australasia and Japan.
He previously worked for Eli Lilly & Company for 17 years in different medical roles as well as marketing and sales. During his different roles, he was based in South Africa, United Kingdom and Australia. Before joining the Pharmaceutical Industry, Danie had his own primary care practice. Danie started his own mentoring, coaching and consulting business, TheNextVersion Ltd, in Jul 2018.
Chief Medical Officer & Executive Vice President, and Head of the Development & Medical Patient Value Practices / UCB
Prof. Dr. med. Iris Loew-Friedrich is Chief Medical Officer for UCB, a member of the company’s Executive Committee and Head of the Development & Medical Practices. She provides strategic global leadership for world-wide clinical development, medical affairs, regulatory affairs, real world evidence, patient safety/pharmacovigilance and external engagement. Iris started her service for patients in the pharmaceutical industry in 1992 with a focus on clinical development in the areas of immunology, bone disease and neurology, delivering together with her teams several novel medicines to patients. She held various positions in Research and Development in different companies, always with a focus on global drug development. Since 2001, prior to joining UCB, Iris was the Global Head of Research and Development at Schwarz Pharma (acquired by UCB in 2006) and a member of their Executive Committee. Iris is a physician, board-certified in internal medicine, with a medical license from the University of Frankfurt where she also holds a visiting professorship at the Medical School. Iris is active in industry associations, a member of different supervisory boards, including the board of TransCelerate. She is passionate about making a difference to the lives of people living with severe diseases.
Head of Medical Affairs Oncology Region Europe / Novartis
Following Graduation in Medicine at the Free University Berlin, Michael pursued a career in General, Cardiovascular and Surgical Oncology gaining an MD and an FRCS. He joined pharmaceutical industry 24 years ago and has since been in clinical development, project leadership, and commercial and medical affairs roles at country, regional and global level. Throughout his clinical and industry career, Michael mainly covered specialty care areas, e.g. Oncology and Immunology. He also qualified as a Pharmaceutical Physician and as an MBA. Research interest and publications are in Oncology and Immunology as well as in general aspects concerning Medical and Clinical Affairs in the Industry
Head of Medical Affairs Turkey & Israel / Sanofi Pasteur
Dr. Baris Ugur is currently Head of Medical Affairs Turkey & Israel at Sanofi Pasteur. He has worked in various therapeutic areas and companies including national and international medical affairs positions (Pfizer / Emerging Markets Europe). He has studied medicine and involved in Public Health doctorate program at Istanbul University. He has an ongoing PhD in Clinical Psychology. He also holds a diploma in business administration.
Extensive and diverse experience in the Pharmaceutical and Healthcare Industry, including R&D, Sales, Sales Training and Medical Affairs. The last 17 years have been in Medical Affairs, predominantly involved in the set up and leadership of field based medical (MSL) teams, after an initial 6 years as an active MSL. As a first line manager developed and implemented an MSL function across a strategic alliance and as a second line manager reorganised the MSL function at AstraZeneca UK, including the successful development of an MSL Excellence scorecard to assess and develop operational MSL Excellence. Extensive stakeholder management experience, at a National, European and Global level, involving medical strategy development and the development of core MSL skills, capabilities and performance assessment.
(MAPS President) / EVP and Head of Medical Affairs / Astellas Pharma
Charlotte M. E. Kremer, MD, MBA is the Executive VP and head of Medical Affairs for Astellas. In this role, Dr. Kremer provides leadership for the Medical Affairs organization globally.
Dr. Kremer joined Astellas in 2012 with 20 years of experience in the pharmaceutical industry. Prior to Astellas, she held the position of Vice President, Therapeutic Area Head for Ophthalmology, PVD, Rare Diseases and Neuroscience at Pfizer. While at Pfizer, she successfully led and executed the clinical development and global medical programs in these respective areas. Prior to joining Pfizer, Dr. Kremer held positions of increasing responsibility providing medical support, developing Phase 3b/4 clinical trials, and initiating and directing a Medical Liaison program at Organon Pharmaceuticals, both in the Netherlands and in the United States. A native of the Netherlands, Dr. Kremer received her medical degree from the University of Utrecht, The Netherlands. She went on to receive her Diploma Pharmaceutical Medicine (DPM) from Universite Libre de Bruxelles. After transferring to the United States, Dr. Kremer completed the Executive MBA program at New York University’s Leonard N. Stern School of Business.
Medical Affairs Manager, TA Cardiovascular (Russia) / Boehringer Ingelheim
Dr. Mikhail Sumin has 8 years of experience in Academic Medical Science and 12 years of working in pharmaceutical industry. He started a career from Clinical operations department of Parexel international and after 6 years he moved to Medical Affairs of Boehringer Ingelheim. Currently Dr. Sumin is a Head of therapeutic area cardiovascular at Medical Affairs of Boehringer Ingelheim Russia. During his professional pathway he has been working within various therapeutic areas such as cardiovascular, metabolism, oncology/hematology and rheumatology. Professional interests and experience of Dr. Sumin are related to development and execution of medical communication strategy, field-based medical affairs functions, generation and using real world evidences, Investigator-initiated studies.
Senior Vice President, Head of Global Medical Affairs Oncology / Eisai / (Former 16'-17' MAPS President)
Dr. Kirk Shepard is the 2016-2017 President of the Medical Affairs Professional Society and has more than 25 years of experience in the pharmaceutical industry. He is a board-certified medical oncologist and hematologist physician. He is currently Senior Vice President, Head of Global Medical Affairs Oncology at Eisai Pharmaceutical Company.
Dr. Shepard’s experience in multiple therapeutic areas includes operational and strategic product development from Phases I through IV and the diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, health economics & outcomes research & patient access, data generation, field-based medical teams (MSLs), PV/safety, medical communication & publications, patient advocacy, and public relations. In 2015, he was selected as one of the 100 Most Inspiring People in the Pharmaceutical Industry (PharmaVOICE).
Before his pharmaceutical career, Dr. Shepard served as a staff physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic Foundation, where he supervised numerous studies in oncology and symptom control. He has more than 50 medical publications in journals and books. Dr. Shepard earned his bachelor’s degree from Cornell University in Ithaca, NY, and his medical degree from the University of Cincinnati Medical School in Cincinnati, OH. He completed both his internship and residency in internal medicine at Case Western Reserve University in Cleveland, OH, and fellowships in hematology and oncology at the University of Chicago Hospitals and Clinics in Chicago, IL.
Chief Medical Affairs Officer / WPP Health & Wellness
Dr. Rick Morton currently the Chief Medical Affairs Officer at WPP Health & Wellness (London & New York) and prior to this position was the Associate Vice President and Head of Value & Access at Allergan, based in the Allergan International Office in Marlow, UK. He received a doctorate in Neuropharmacology from the University of Manchester, UK and has a B.Sc (Hons) degree in Pharmacology from the University of Liverpool, UK. Rick has extensive academic, biopharmaceutical industry and global healthcare consulting experience, across a diverse therapeutic range, notably, neurosciences, ophthalmology, rheumatology, urology, gastroenterology and immunology.
Rick has previously been head of function in Allergan’s Medical Affairs and HEPRA for the EAME region and prior and to this worked in Switzerland for Novartis Pharma as a Global Access Lead on early pipeline development assets. He has also extensive drug development and commercialization experience from working as Vice President, Consulting at PAREXEL in addition to a previous role as MD of the Global Market Access consultancy, WG Consulting. Rick has also extensive biopharmaceutical industry experience with G.D Searle, Pfizer and Yamanouchi, and prior to this was in academia as a lecturer in Pharmacology and Physiology at Wolverhampton University, UK. Rick is passionate about the critical role of medical affairs in the planning and execution of pre, peri and post launch patient and market access strategies that guide effective healthcare product development and commercialization.
PARADIGM / Coordinator European Patients’ Forum / France
Mathieu Boudes, PhD, joined the European Patients’ Forum (EPF) in 2018 as coordinator of the PARADIGM project, a public-private partnership financed by the Innovative Medicines Initiative and co-led by EPF and EFPIA (European Federation of Pharmaceutical Industries and Associations).
Strong of 34 partners (patient organisations, pharmaceutical / biotech companies, regulators, HTA bodies and academic teams), PARADIGM (for Patients Active in Research and Dialogues for an Improved Generation of Medicines) will strengthen the understanding of stakeholders’ needs, the systems-readiness, ensure maximum synergies with other initiatives and develop an inventive and workable sustainability roadmap.
Previously, Mathieu worked for EURORDIS-Rare Diseases Europe since 2013. Mathieu was involved in activities to foster the access to innovation to patients.
Head, Global Field Based Medical Excellence & Insights/ Global Medical Operations/ Sanofi Genzyme
Dr. Robin Winter-Sperry started working in the industry in the area of Dermatology. She has had a long and distinguished career including Sanofi/Genzyme Global Medical Affairs, Strategy & Tactics in the area of Multiple Sclerosis and President and CEO of Scientific Advantage, LLC. She created Novartis’ Medical Science Liaison (MSL) department of Scientific Operations and Sanofi-Synthelabo’s Medical Therapeutic Liaison division.
She has been involved in over 28 product launches. She has pioneered the recognition of MSLs as a specialty in the biopharmaceutical and device industry and is responsible for creating and developing many of the industry’s leading Medical Affairs and Medical Liaison teams.
Former Medical Director and Head of Medical Affairs (Russia) / Boehringer-Ingelheim
Alexandra Safronova, MD is currently Medical Director and Head of Medical Affairs at Boehringer-Ingelheim, Russia.
Dr. Safronova earned her medical degree from Moscow Medical Academy cum laude. She completed her residency in internal medicine at Moscow Medical Academy, and fellowships in intensive care at Pirogov Medical University and endocrinology at the Russian Medical Postgraduate Academy.
Before her pharmaceutical career, Dr. Safronova served as a staff physician in the Cardiology and Intensive Care Department at Medical Center of the Russian Academy of Science.
Dr. Safronova started her career in the pharmaceutical industry in 1999 as Clinical Research Scientist at GlaxoSmithKline, then she worked as Manager of Clinical Operations at Quintiles (now IQVIA).
In 2010 she joined Teva as Director of Clinical Research. Her primary task there was to set up Clinical Research Department from the scratch to support registration of new products and supervise global studies. Within two years Teva became #1 in clinical research in Russia. The company received 7 new market authorizations supported by the results of clinical program developed and executed by the department headed by Dr. Safronova. In 2013 Dr Safonova focused on building Medical Affairs function as Medical Director of Russia and CIS, Teva Pharmaceutical.
Dr. Safronova’s experience in multiple therapeutic areas includes Phases I-IV and diverse disciplines of medical affairs and product commercialization, such as leading office based and field-based medical teams (MSLs), PV/safety, Regulatory Affairs, Medical information, Patient Advocacy.
Global Medical Lead – Orphan Diseases / Vifor Pharma
Peter Rutherford is Global Medical Lead for Renal Rare Disease at Vifor Pharma in Zurich, CH. He qualified in Medicine at the University of Newcastle upon Tyne, UK and completed postgraduate medical training to obtain MRCP in 1989. He entered an academic training pathway in Nephrology with an MRC Training Fellowship allowing him to complete a PhD in cell physiology as well as completing clinical training in Nephrology and Internal Medicine. He was then an MRC Travelling Fellow at Yale University School of Medicine gaining additional academic experience in molecular biology.
After return to the UK as Lecturer in Medicine at the Unversity of Newcastle, he was appointed as Senior Lecturer in Nephrology at the University of Wales College of Medicine and Consultant Nephrologist. In this role, he combined clinical practice in delivering a full range of nephrology services with academic work. Peter then developed expertise as a clinical leader in the hospital and became the Medical Director of a combined acute, community and mental health NHS organization leading on patient safety, clinical effectiveness, service improvement and research. In addition he was a Clinical advisor at NICE and chaired their Guidelines Review Panel until he joined Pharma in 2007.
From 2007 to 2015 he was Medical Director Renal for Europe, Middle East and Africa at Baxter Healthcare – being responsible for all aspects of Medical Affairs activities across the region. He worked on research projects in patient support, decision making and education as well as new product development for home dialysis. From 2015 to 2017 he was Head of Integrated Market Access at Quintiles in Europe and Emerging Markets – supporting small and large Pharma and emerging biotech companies with medical affairs, medical communications, market access and patient centric services. Focused on launch brands, Peter support a range of companies across a range of therapeutic areas. Since joining Vifor Pharma, he is back on home ground in Nephrology but working in systemic diseases affecting every organ system.
Senior Medical Director, Head of BGx, International Markets / Teva Pharmaceuticals
Dr. Alexander Semenov received his medical degree from Lviv National Medical University, Ukraine, where he also pursued specialty training in General Surgery, completed it cum laude and worked in regional hospital a couple of years. Next to medical degree Alexander is certified in Marketing by Edinburgh Business School of Heriot-Watt University.
Alexander started his professional pathway in pharmaceutical industry 16 years ago in Pfizer (in 2002). The last 15 years he devoted to Teva and its affiliates, where he had various leading positions in different functions – Sales and Marketing, Portfolio and Business Development, Quality Assurance, Regulatory Affairs and since 2010 he has been holding the Country Medical Director position in Ukraine.
Besides this Alexander is the member of Medical Affairs Leadership Team in the region “International Markets” that embraces LATAM, EMIA and APAC. On the regional level Alexander acts as the Senior Regional Medical Director and is responsible for providing medical governance and medical support for branded generics.
Medical Affairs Manager, Respiratory TA, Region RCV (Vienna) / Boehringer-Ingelheim
Dr. Maria Sanzharovskaya, MD, PhD has 12 years’ experience in Pulmonology and Clininal Allergology working in clininc and on the chair of Internal Medicine performing scientific and educational work. During this period 53 papers were published in COPD area, presentations during European Respiratory Congresses several times were sponsored by European Respiratory Society. Participated in more than 20 clinical trials in respiratory area as investigator. Maria made Research Fellowship in Instituto Hospital del Mar de Investigaciones Médicasin Barcelona in muscle disfunction hypercapnia.
She started her pharma career at Boehringer-Ingelheim as a Medical Advisor responsible in the respiratory area.
After 2.5 years Dr. Sanzharovskaya moved to Vienna where she was responsible for scientific support in the respiratory area for 18 countr
Vice President, Global Ethics & Compliance / Ipsen Pharma
Giota is a senior professional with over eleven years of experience in Ethics & Compliance and Internal Controls in multinational pharmaceutical companies.
In March 2015, Giota joined Ipsen and since then she has been responsible for the development and enhancement of the Global Internal Ethics & Compliance Program and she has been the Ethics & Compliance Officer for the Global Teams reporting to the Ipsen’s Chief Ethics & Compliance Officer. In February 2016, in addition to her global responsibilities, Giota also took over the oversight of the Ipsen China Ethics & Compliance Program’s evolution and in January 2018, France has been added under her oversight.
Previously, Giota was Country Compliance & Ethics Officer for various European countries and Contributor to the European Compliance & Ethics Program in Bristol-Myers Squibb based in Paris and Athens and earlier, she held various positions in Business Controls in the same company based in Athens.
She received a university degree on Management Science & Technology from the Athens University of Economics and Business and completed the Sciences Po European Healthcare Compliance, Ethics and Regulation Programme and the Insead Healthcare Compliance Implementation Leadership Programme – Part II.
Giota speaks Greek, English and French and she is member of the ETHICS Association.
Global Head of Vaccines Field Medical Program / Sanofi Pasteur
Jorge´s current role is Global Head of Vaccines Field Medical Program in Sanofi Pasteur. In this function he is in charge of coordinating several initiatives related with Medical Science Liaison team.
Jorge was born in Mexico City, and graduated from the National University of Mexico. He is a Biologist and holds a master’s degree with honors in Neurosciences.
Jorge joined Sanofi in 1991 and he drives his knowledge in Sales, Marketing, Business Support, e-business, training and Medical through more than 25 years of experience holding various roles in Pharma Mexico. Jorge joined the Latin America region team in 2010 and, since 2015, he has been coordinating several important initiatives at a Global level in Sanofi Pasteur. Those multidisciplinary functions provide to Jorge an interesting transversal view of the Pharma environment.
When not traveling to train teams, Jorge enjoys writing science fiction short stories and reading. He also loves savoring food of the world (his biggest challenge: a crunchy and spicy scorpion in a Beijing market!)
Vice President, Global Medical Affairs Services / Ipsen Pharma SA
Dr Mónica de Abadal is an Executive Leadership Committee Member of the Medical Affairs Professional Society EMEA with more than 16 years of experience in the pharmaceutical industry
Dr de Abadal has experience in multiple therapeutic areas, including oncology, endocrinology and movement disorders as well as operational and strategic Medical Affairs experience in diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, quality management systems, data generation, field-based medical teams (MSLs), safety, medical communication & publications
She has served as a board member in companies specialized in telemedicine and has international Medical Affairs experience in Europe, APAC (Australia) and global positions, including deputy Chief Medical Officer, Global Head of Publications. She currently holds the VP Global Medical Affairs Services group position at Ipsen.
Dr de Abadal obtained her medical degree from the University of Barcelona and entered residency in Anaesthesiology in Hospital Vall d´Hebron (Barcelona) ). She validated her medical degree in the US (USMLE) and obtained an MBA specialized in Healthcare administration from (USF) and a postgraduate diploma in Pharmaceutical Medicine (UAB).
Malcolm is Managing Director, of PharmaMedic Consultancy Ltd a London based International biosciences consultancy company, and Immediate Past President of the Section of Pharmaceutical Medicine and Research of The Royal Society of Medicine, London, UK.
With over 20 years experience as a Consultant Pharmaceutical Physician to Industry and Government, Malcolm advises bioscience and pharmaceutical companies on Product Development, Regulatory Strategy and Medical Affairs, focusing on Start-Ups and SMEs. He acts as a Clinical Specialist and Chair to the European Commission’s Biomedical Research Programme (Horizon 2020), lectures in both Europe and the United States on medicinal development, and teaches on the Pharmaceutical Medicine and Regulatory MSc Course of Copenhagen University.
Following a first degree in Physiology at King’s College London, Malcolm qualified in medicine from St Bartholomew’s Hospital, in 1993. After postgraduate training in General and Intensive Care Medicine he joined the UK Government as a Medical Assessor in new medicines in 1997. After senior industry roles at Pfizer and AstraZeneca he re-joined Government as Lead Medical Assessor to the UK Dept of Health’s Clinical Trials Unit on it’s formation in 2005, and worked with the European Medicines Agency (EMA) on the development of a trans-European clinical development process in the pharma and biotech sectors. Leaving full time employment with the Government in February 2007, Malcolm was appointed as an Independent Consultant to the Dept of Health.
He has worked extensively in senior UK and Global consultancy positions with most of the top ten pharma companies including AstraZeneca, Eisai, Roche, Novartis, Schering-Plough / MSD and GSK, in addition to having advisory development roles in the biotech, device and generic pharma sectors.
In 2012 he was appointed President to the Section of Pharmaceutical Medicine and Research at the Royal Society of Medicine, London and in 2014, a Fellow of The Royal Society of Biology.
Senior Director / Head of HTA / Strategy and Communication / ICON plc. / United Kingdom
Dr. Bending is a Health economist with a PhD in Health Sciences studying the use of HTA in reimbursement decision-making with over 13 years (>100 HEOR/MA projects) consulting experience. He is Head of the HTA, Strategy and Communication team and Senior Director at ICON.
Dr. Bending developed early HTA and payer engagement services in ICON and has experience of more than 40 formal integrated HTA scientific advice engagements across a range of disease areas. He completed a PhD fellowship on the use of Health Economic Analysis in OECD countries’ pharmaceutical systems and its contribution to decision-making. He has presented at international conferences and published over 30 reports/papers and been involved in more than 100 HEOR and market access consulting projects. Dr. Bending was a co-author of a study that won the Egon Jonsson award in 2009/2010 for most outstanding paper published in the International Journal of Technology Assessment in Health Care on the harmonization of HTA across countries.
Dr. Bending provides senior leadership for large projects on strategic market access and Health Technology Assessments (HTAs) for pharmaceutical, vaccine, and medical device companies. His experience is wide-ranging, from projects for international HTA submissions, HTA scientific advice, value proposition development, market access, systematic literature reviews, health economic models, payer advisory boards, and global value dossiers.
Prior to joining ICON, Dr. Bending was a Senior Consultant at York Health Economics Consortium, working on projects for the National Institute for Health and Care Excellence, Department of Health, Patient Safety Research Portfolio, General Medical Council and more. Dr. Bending has a PhD in Health Sciences from the University of York and his thesis explored the use of HTA in international reimbursement decision-making. He also has an MSc and BSc honours in Economics from the University of Warwick.
Alex is one of the world’s leading experts at the intersection of health and technology.
Working in the pharmaceutical industry for 20 years, for the last 15 years he has lead the digital transformation of healthcare, both from within the industry at Johnson & Johnson and servicing the industry by founding and leading multiple award-winning agencies. Most recently he co-founded Foundry3 which houses the world’s first digital health innovation Lab focused on the pharmaceutical industry, the ‘Innovation Foundry’.
Alex pioneered the application and integration of new philosophies and technologies within pharma, launching the first digital only marketing campaign supporting a pharmaceutical brand, he was the first to utilize social media and he commissioned and designed mobile health applications before the advent of the app store.
This led to numerous digital marketing and communications awards, the inaugural recipient of the Global Social Media Pioneer award in Philadelphia in 2010 followed by the James E Burke Marketing Award for Uncommon Courage in 2011, the first pharma professional recipient. He has won over 30 PM Digital awards and the prestigious AXA PPP Global Health Technology Award 2017 with his work displayed in the Design Museum in London.
Alex has been the brain child of ground breaking digital health solutions in respiratory disease, Pulmonary Arterial Hypertension, transplantation, opioid addiction, MS, diabetes and psoriasis among others.
He is also an invited member of the Wharton Global Advisory Board on the Future of Advertising and a Fellow of the Chartered Institute of Marketing (FCIM).
As Senior Vice President, Client Success, Amanda is Within3’s utmost client advocate. She leads the team that is accountable for guiding clients through the process of defining their program objectives and expectations, aligning Within3’s online discussion platforms to exceed client performance outcomes, and championing the client-centric culture that consistently results in delivering meaningful, measurable results.
Amanda began her career in 1997 in the world of computer hardware product management and procurement. In 2004, she shifted gears and applied her management skills to client services, in the arena of medical communications, with an emphasis on digital solutions.
Amanda has held product management and procurement roles at Intel Corporation and Micro-Star International and leadership roles in client services for Healthcare Consultancy Group (Omnicom) and PSL Group.
Her intuition, proactive nature, and attention to detail, have fostered lasting relationships with her clients. She listens closely and puts herself in the client’s shoes, in order, to be consultative and provide direction that will ultimately result in the achievement of their program goals and objectives.
Over the course of her tenure, Amanda’s strength has always been client-focused. Her dedication, passion, and commitment to client service has been the forefront throughout her career.
Erik Briers holds a doctorate in Chemistry (1979) from the University of Leuven, Belgium. After teaching chemistry and physics, Briers served from 1979 until 1980 as the Head of the department for biochemistry, at the Central Medical Laboratory in Antwerp, Belgium.
From 1980 to 1982 Briers worked as Head of scientific services for bioMérieux in the BENELUX. In 1982 Briers founded a biotech company ECO-BIO. ECO-BIO was an in vitro diagnostics company specialised in microbiology and immunology. One of the products for the detection of Aspergillus antigens (galactomannan) Dr Briers developed has FDA approval.
Since 1990 Briers is CEO of Beta Ventures, consulting the in vitro diagnostics industry and publisher of specialised media on laboratory medicine – Focus Diagnostica.
Dr Erik Briers is a past guest lecturer for the subject “Trends and Innovations in the Biomedical Sector” within the Master study programme Bio-Engineering at the University of Leuven Faculty of Engineering Technology 2009-2016 and is a science and medical writer.
Doctor Briers strong social involvement within patient organisations began after his own prostate cancer diagnosis in 2001 and successful radical prostatectomy treatment with no signs of recurrences until today.
He joined the Belgian patient support group “Us Too Belgium” and is one of the founders of EUROPA UOMO, the European Prostate Cancer Coalition. Today he is prostate cancer advocate and editor of the patient magazine “PROSTAATinfo” for the Belgian chapter.
He was the Executive Director of the European Cancer Patient Coalition (ECPC) (2012-2013) and Executive Director ad interim of EPPOSI (European platform for patient organisations science and industry) a multi-stakeholder think tank in health policy-making in 2014.
He is an alternate patient member of the Committee on Advanced Therapies (CAT) of the European Medicines Agency (EMA) (2016-2019). He is also patient member of the Guidelines Committee of the European Association of Urology (EAU) on prostate cancer.
Nick Broughton is the Managing Director of Ethos, a company specializing in education and behavioral change in the field of pharmaceutical ethics and compliance. He is a pharmaceutical physician with over 20 years of experience within the industry, including senior medical roles in the UK and European Medical and Regulatory Affairs for AstraZeneca and Celgene. He is actively involved in advising large and small pharmaceutical companies on their promotional and other activities.
Nick has post graduate qualifications in medical ethics and law from Keele University, UK. The educational program has been developed to draw heavy on theories of medical ethics and their practical application in business decision-making and commercial campaigns.
Nick is a member of the Faculty of Pharmaceutical Medicine Ethics and Practice Committee.
Helen Kane is the Managing Director of PIVOT MSL, a specialist training consultancy with a core focus on driving excellence throughout the global MSL community.
A pharmacist by background she spent more than two decades working in medical affairs across the life science industry. With a strong track record in the development, management and leadership of MSL teams she was a founding member of the UK professional association for MSLs, and served as Chair 2012-15. Through her many activities she has acquired a reputation and profile as the leading, independent driving force behind the concept of MSL excellence. Respected as a trainer, facilitator, mentor, speaker and expert contributor, Helen believes that ‘it is indeed a beautiful thing when a passion and a career come together.’
PIVOT MSL was established as a training consultancy from a belief in the value and impact of the MSL, and a desire to support the wider medical affairs community. Helen is proud to work with a team of selected industry experts who are connected by their desire to transform both individuals and teams. Distinguished by its expertise and a portfolio of innovative training programs for both MSLs and their leaders, PIVOT MSL is regarded as a trusted, go-to resource by clients throughout the world.
General Manager / Kantar Health: Real World Evidence
Mr. Fronstin joined Kantar Health in 2005 and is currently the General Manager of the US Real World Evidence (RWE) Team. Mr. Fronstin is responsible for the commercial strategy, sales and operations, and new product creation and execution related to RWE. Additionally, Mr Fronstin is accountable for the Subject Matter Experts working with and satisfying clients.
As a member of Kantar Health’s leadership team, Mr. Fronstin oversees the US Real-World Research and Value strategy initiative and the Patient Centered Research (PaCeR) Program; syndicated products such as the National Health and Wellness Survey, Epi Database® and integration of other available RWE, Kantar and WPP databases.
Mr. Fronstin has broad experience in the healthcare industry. Prior to joining Kantar Health he held various commercial and marketing positions at Humana, Merck & Company, the Johnson & Johnson/Merck joint venture, and TargetRx.
Mr. Fronstin earned a Master of Business Administration from the University of Miami with a focus on healthcare administration. He’s been recognized as a thought leader in health outcomes as well as for various therapeutic areas.
Senior Vice President, Business Partnerships/ Within3
With more than 20 years diversified experience in the life sciences industry, Peter has been involved in digital pharmaceutical communications since 1996. His leadership in strategic planning, revenue generation, and business partnering has established a strong and diverse client-base for Within3. He continues to work closely with existing and new clients as they expand use of Within3’s solutions, introduce new use cases, and strive to push the envelope of innovation within their organizations engaging healthcare professionals, payers, and patients.
His expertise and experience in working closely with organizations to adopt new technologies proves invaluable to clients and partners. His consultative demeanor and willingness to work collaboratively continually provides benefits to clients and partners. Peter leads a team focused on driving market growth and new business nationally and globally by identifying and nurturing opportunities, forging close working relationships with clients and partners, and driving revenue for Within3.
Prior to his tenure at Within3, Peter was a part of the leadership team for Hyphen, an Omnicom-owned digital agency, Peter developed and implemented strategies that established Hyphen’s market presence, grew product offerings, and drove business development and customer acquisition. Hyphen grew exponentially from 2003 to 2008, quadrupling staff and revenues while acquiring new clients and opportunities annually. Peter has also held positions with Sermo, Peer Direct, Torre Lazur, and Commonhealth developing business and leading accounts. Peter has worked extensively across the industry resulting in successful innovation for clients and customers alike.
Omar has more than 25 years of leadership and strategic experience in HEOR, Market Access, Medical Affairs, Pharmacoepidemiology, and disease and safety registries in biotech, pharmaceutical, academia, and medical device settings. Currently, he is the VP, of HEOR & RWE at AveXis, a gene therpay company. Prior to joining AveXis he led the value and access activities at Halozyme. At GSK Omar developed and led the Global Value Evidence Analytics focusing on innovation and ensuring high quality of payer research including clinical trials and HEOR studies. Prior to joining GlaxoSmithKline he led the global health economics and outcomes research at Takeda, the Pharmacoepidemiology and Registry activities at J&J, and the Biostatistics/Epidemiology/Data Management and Analytics Departments at University of Massachusetts Medical School. He held a number of key industry roles and academic positions and is Adjunct Professor at the School of Pharmacy, University of Illinois, Chicago. Omar was recently recognized as one of the top 50 most influential people in Big Data. He is a leader in digital health. Omar is an author and co-author of more than 250 peer-reviewed publications.
Omar trained at Monastir School of Medicine in Tunisia, before taking his MPH at University of Massachusetts School of Public Health. He also has a Diploma in International Health and Medicine of Catastrophe from Tours Medical School in France. Omar also earned Certificates from Harvard University in Pharmacoeconomics and Outcomes Research and from Kellogg’s School of Business in Business Marketing Strategies and Marketing Healthcare Products. He lived in 5 continents and is fluent in 4 languages.
Dr. Maru is an academic physician, Neuroimmunologist and health economist with extensive global experience in clinical research and development, translational medicine, health economics, real-world evidence, and medical affairs.
With a specialty in economic modeling and real-world evidence generation, Benit’s scientific and industry career has primarily focused around neurology, neuroimmunology, immuno/haemato- oncology, and biological therapies for inflammatory diseases, nephrology, dermatology and rheumatology, and rare/ultra-rare disease.
Dr. João Dias is an honors graduate of the University of Helsinki. He received his Licentiate/MSc in biochemistry from the Universities of Porto, Portugal and Wageningen, the Netherlands; and his PhD studies in Immuno-Oncology and Gene Therapy at Helsinki University Central Hospital and Helsinki University, faculty of Medicine.
He is currently responsible for international medical affairs and clinical development for the medical devices and diagnostics portfolio at Haemonetics which includes Hemostasis Management, Cell Salvage and Transfusion Management products. Prior to this role, João had a variety of roles of increasing responsibility in the areas of both market access and medical marketing.
He has authored several peer-reviewed publications and white papers in the fields of Hemostasis, Patient Blood Management, Immuno-Oncology, Gene Therapy, Hematology, and Molecular Biology.
Prior to his tenure at Haemonetics, João worked as a scientist in the development of new products in Cancer Gene Therapy and served as a Life Sciences Consultant working together with multiple global life-science companies.”
Chief Patient Affairs Officer, Global Medical Affairs / Ipsen Pharma
Isabelle Bocher -Pianka has over 25 years of international Management experience in the pharmaceutical and consumer goods industries, leading cross-functional and country teams across the globe. From her previous Senior Vice President role, leading the Global Neurosciences Franchise at Ipsen , she was appointed to the new transformation role of Chief Patient Affairs Officer reporting to Global Medical Affairs in March 2016
Her mission at Ipsen is to ensure that “the people we care about are at the center of the decisions we make.”
She is the internal and external reference patient ambassador, responsible for driving and promoting the patient centricity vision and strategy along the entire value chain of Ipsen’s therapeutic areas (Oncology, Neuroscience and Rare diseases) and across all divisions and geographies.
In developing Patient Centricity within the company, Isabelle supports the sourcing and internal dissemination of patient’s insights, needs and priorities in order to shape Ipsen’s business to positively impact patient outcomes.
Vice President for Medical Affairs Strategy / Medmeme
Dr Schweiger is a senior medical affairs executive and pharmaceutical entrepreneur. He has led medical affairs for both multi-national and small pharmaceutical companies and has vast experience in building and selling pharmaceutical assets in small biotech organizations. He will be an ambassador for Medmeme across Europe
Lori Mouser is the Global Head of Medical Science Liaisons (MSL) at F. Hoffman La Roche. She champions the success of MSLs to advance medicine through their engagements with healthcare providers. Leading MSL teams for over 17 years, Lori brings the experience from a range of therapeutic areas. She has US and Global exposure and operates with a commitment to creating solutions through collaboration.
Lori’s first MSL position was at Aventis (now Sanofi) where she quickly gravitated to leading MSL teams during her 12 years with the company. Joining the Roche organization at Genentech in 2012, Lori ultimately had responsibility for the national US Oncology MSL and field leadership teams. Building upon that background, Lori expanded her scope in 2017 to serve the Roche global organization in her current role.
Lori holds a Doctor of Pharmacy Degree and prior to the pharmaceutical industry, she had an
academic career as an Associate Professor in Clinical Pharmacy at Washington State University.
Chairman of the Board of Management/IGES Institut GmbH/
Bertram Häussler is the chairman of the IGES Group, a corporation of research and consulting companies specializing in infrastructure and health care. He is a medical doctor, sociologist, and honorary professor of Economics of the Pharmaceutical Industry at the Technical University (TU) Berlin. His research work focuses mainly on industrial economics, health services research, health economics, benefit assessment in medicine as well as drug development in a national and international context.
Head of Therapeutic area- Respiratory / Boehringer Ingelheim-Russia
Dr. Nikolay Voznesenskiy joined pharmaceutical industry 6 years ago after 18 years of experience in research and clinical practice in the respiratory medicine. Dr. Voznesenskiy made his research and PhD thesis on the topic “Exhaled nitric oxide as a biomarker of bronchial asthma” at the Pulmonology Research Institute (Russia).
He started a career in Medical Affairs at Chiesi as a Medical advisor. Then he moved to Medical Affairs of Boehringer Ingelheim. Currently Dr. Voznesenskiy is a Head of therapeutic area Respiratory at Medical Affairs of Boehringer Ingelheim Russia. Professional interests of Dr. Voznesenskiy are related to development of medical communication strategy, implementation of new approaches to external experts development and to continuous medical education.
Executive Director and European Head of Scientific Affairs / Amgen
Michael Hamann is Executive Director and European Head Scientific Affairs at Amgen, responsible for all medical education and scientific exchange activities across all of Amgen’s therapeutic areas in Europe. He joined Amgen in 2005 as European Head for their Regional Medical Liaisons (RMLs). In 2008 he became Executive Director for Scientific Affairs building and leading the European Teams and Capabilities for Regional Medical Liaisons, Medical Communications, Medical Information, Scientific Publications, Training and Development and Patient Affairs. Michael has been working for more than 20 years in the pharmaceutical industry, and obtained his PhD in Physiology at the University of Marburg, Germany. He started his industry career at Eli Lilly in Germany in 1994 in diabetes research, and has held various management positions, including Head of Quality Assurance in manufacturing, responsibilities in Project Management and Medical Affairs.
Vice President, Medical Affairs Strategy / Medmeme LLC.
Joseph B. Laudano, BS Pharm, Pharm D, is Vice President, Medical Affairs Strategy at Medmeme LLC. Dr. Laudano has over 30 years’ experience in the pharma industry. Before joining Medmeme, he was Vice President of Medical Affairs at Alliqua Biomedical. Before joining Alliqua Biomedical, Dr Laudano was Senior Director of Medical Affairs and head of Publication Planning at Forest Research Institute. Prior to this he spent 20 years at Roche Laboratories in Medical Affairs and Marketing in various roles including; Director of Medical Information, Product Director and Medical Liaison. Dr. Laudano has extensive research experience in several different therapeutic areas including infectious diseases, dermatology and oncology and has authored numerous publications and scientific posters.
Whether in research projects or project assignments, Dr. Laudano has always had a passion for recognizing trends and signals in data and product information. As director of Medical Information at Roche, he was the first to develop a qualitative reporting system on product inquiries which provided product teams trends in medical inquiries and other information. His passion for “analytical inquiry” serves him well at Medmeme where he works with the leadership team on developing Medical Affairs strategies and creating of new processes and applications for Medical Affairs Professionals.
When not at work, Dr. Laudano enjoys time with his wife, Kathleen and family. His hobbies include fishing, winemaking, cooking, gardening and wood working. He maintains a Master’s Captains Licence and volunteers hundreds of hours each year as a coxswain, vessel examiner and aids to navigation verifier with the United States Coast Guard Auxiliary and has received numerous awards and commendations in this capacity.
David McNaughton has 23 years’ experience in the Pharmaceutical industry working for a variety of small and large companies in therapy areas from vaccines to Oncology. It was during this time in Oncology at Pfizer that David attained his first insight into the importance and ‘value’ that MSL teams can bring, after seeing the huge impact they made on the successful introduction of Sutent for RCC & GIST patients.
Eleven years ago, David left Pfizer to set up STEM with Rob Wood, with the objective to help companies accelerate performance by ‘benchmarking’ their internal and external alignment to product plans. Initially this looked mainly at the Sales Teams alignment to strategy, messaging and execution, but over the last 4 or 5 years has evolved to also look at the Field Based Medical Expert role. This reflects the growing importance companies are placing on MSLs when it comes making sure the right patients are getting the right medicines as well as a growing desire to understand the ‘value’ these teams are adding.
The last 5 years have given us some very interesting ‘benchmark’ data that looks at what the MSLs believe their role to be, how it is evolving and how they then go about executing that role… and a great insight into how we might be able to benchmark ‘value’.
Medical Affairs Business Partner, Medical Affairs Interim Management and Consulting / Independent Freelancer / Giesen Medical Affairs
Today, Medical Affairs must be more than just medicine.
Dr. Giesen is an independent medical affairs expert with the ability to combine medical profession and passion with business objectives.
She supports and advises pharmaceutical companies and external service providers within the pharmaceutical industry in the area of Medical Affairs, including medical product management and marketing, medical communication, MSL and medical information management. Her work focuses on conceptual strategy development and its operational and concrete implementation. She is motivated by her curiosity and her enthusiasm for both medical and entrepreneurial topics, for which she also likes to develop unconventional solutions.
Prior to her independent Medical Affairs business, Dr. Giesen gained nearly 15 years of experience as an employee within the pharmaceutical industry at Novartis Pharmaceuticals, Novartis Vaccines and GSK Vaccines. As Global Medical Director, Medical Advisor, MSL and Medical Affairs Project Manager in the national and international Medical Affairs business she was involved and showed extensive cross-functional leadership in numerous and diverse activities and projects within Medical Affairs, R&D, Marketing and Sales, Quality, RA, PV, Health Economy &Policy and Market Access.
Dr. Giesen is a certified veterinarian, has a doctorate degree in basic pharmacological research and holds an MBA in General Management.
Senior Vice President and General Manager / Tardis Medical
Andrew is a charismatic leader who has over 30 years’ experience in the pharmaceutical industry in a variety of senior positions.
Working with top 10 pharma, specialty healthcare and biotech companies alike, Andrew has a passion for connecting the pharma industry with the people that matter: patients, decision makers and leaders of opinion to create strong and positive debate.
Creating enduring, transparent and ethical relationships throughout the development and launch processes for new products significantly improves the uptake and therefore patient access to new medicines. Tardis Medical has been built around developing tools, techniques and processes to enable positive peer-to-peer conversations, which enhance the reputation of the pharmaceutical industry.
This approach forms the foundations of Andrew’s work consulting with Medical Affairs organisations globally, where his specialist areas of knowledge are; patient and HCP engagement and education, strategic developments in the role of the MSL and Operational Excellence, which includes systems, processes and MSL capabilities
Ian has over 30 years in pharmaceutical development and medical communications, including 4 years as a Medical Affairs Consultant to pharma and Medical Communication agencies and 10 years as a Global Medical Affairs Leader in AstraZeneca Oncology franchise delivering multinational communication programs. He has experience across many functions including Medical, Marketing, Operations and R&D.
Ian has extensive experience in the development of strategic medical plans for a number of oncology products and translation into effective multi-national programs to support communication to worldwide affiliate companies. He has led cross-functional teams to deliver insight-driven, customer-focused target product profile and claims documents to drive delivery of differentiated reimbursable medicines. Ian also has extensive experience in the delivery of medical excellence training programs to global and affiliate medical staff for a number of large Pharma companies. He now provide Medical Affairs expertise across the agency to support medical communication and training programs.
Sital Kotecha has been in the role of Medical Affairs Strategy Director for Europe since July 2016. He is responsible for evolving and executing the Veeva Medical Strategy across Europe focussed on redefining the experience stakeholders have with the industry – with a lens on engagement, confidence build, evidence generation and deriving value from medical insights. He is also responsible for Events Management capabilities that span Medical and Commercial. He comes with Life Sciences experience having worked at AstraZeneca for 6 years in a variety of roles, most recently as Global IT Director for Global Medical Affairs & Global Commercial where he partnered with the function to deploy capabilities and processes to enable medical affairs to deliver on its business strategy both globally and locally. Prior to this role as Head of IT for the AstraZeneca UK where he led the rollout of Veeva CRM. He has 10 years of programme delivery experience with Accenture and started his career as a Pharmacist.
Senior Director / Medical Affairs Strategic Solutions
Dr Peters serves as Senior Director, Medical Affairs Strategic Solutions, a division of Medscape. She brings over 35 years of experience in medical affairs, medical education, research, and publishing to her work. After 15 years as a researcher focusing on immunological and oncological disorders, Pam turned her attention to the data-driven optimization of healthcare at which time she joined Medscape. Prior to her current role, she served as Senior Director, Oncology Education. Pam has a doctorate in immunology and genetics from Yale University and completed her post-doctoral work in immunology at University of California, Berkeley.
Global Business Unit Head, Medical Affairs / Envision Pharma Group
Anne Clare brings a wealth of experience in pharmaceutical communications garnered during her 20 year career leading medical strategy and communication agencies. As Medical Affairs has evolved, Anne Clare has been at the forefront of innovation in agency delivery, transforming both approach and service offerings to address the expanding scope and requirements of Medical Affairs clients.
Having begun her career at Ashfield Healthcare Communications in 2000, Anne Clare supported multiple therapy areas and product launches prior to joining Envision Pharma Group in 2016 as part of the senior leadership team with a remit to expand the European medical strategy group. Having successfully grown the team, Anne Clare now leads a dedicated 45-strong group and has established a strong presence for Envision in the talent-rich hub of NW England.
With a keen interest in patient engagement, Anne Clare is one of the industry’s leading proponents tackling the lack of consistent and evidence-based practices for patient partnership within life science communications as well as exploring how patient advocates and medical affairs teams can work in partnership towards shared goals. Last year, Anne Clare launched a new centre of excellence within Envision Pharma Group dedicated to Patient Partnership in Medical Affairs and Publications. Comprising a team of industry experts, the Envision the Patient team are leading the industry debate on the removal of barriers for patients wanting access to high quality, fair-balance scientific content.